PCP
ANIK icon

Proficio Capital Partners’s Anika Therapeutics ANIK Stock Holding History

Proficio Capital Partners’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-159
Closed -$6K – 213
2019
Q2 		$6K Sell
159
-13
-8% -$474 ﹤0.01% 1116
2019
Q1 		$5K Buy
+172
New +$5.89K ﹤0.01% 1089

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Proficio Capital Partners's ANIK Position: Q3 2019 in Review

Proficio Capital Partners sold out of Anika Therapeutics (ANIK) in Q3 2019, closing a stake of 159 shares — an estimated $6K sold.

Proficio Capital Partners first reported a position in ANIK in Q1 2019 and held it in 2 quarters. The position peaked at $6K in Q2 2019. 194 funds tracked by Wall St. Rank hold ANIK as of Q3 2019.

  • Proficio Capital Partners reported no remaining Anika Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Proficio Capital Partners sold 159 Anika Therapeutics shares in Q3 2019, an estimated $6K.
  • Proficio Capital Partners first reported a position in Anika Therapeutics in Q1 2019 and held it in 2 quarters.
  • Proficio Capital Partners's Anika Therapeutics position peaked at $6K in Q2 2019.
  • 194 funds tracked by Wall St. Rank held Anika Therapeutics as of Q3 2019.

Based on Proficio Capital Partners's 13F filing for Q3 2019, filed 13 Nov 2019.